Rnai-mediated inhibition of ocular targets

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/11 (2006.01) A61K 31/713 (2006.01)

Patent

CA 2595678

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open- angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; .beta.1- and .beta.2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na-K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

Selon l'invention, l'interférence ARN permet l'inhibition de l'expression ARNm d'une cible d'hypertension oculaire dans la réduction d'une pression intraoculaire élevée chez des patients présentant un glaucome à angle ouvert ou une hypertension oculaire. Les cibles d'hypertension oculaire comprennent l'anhydrase carbonique II, IV et XII; les récepteurs adrénergiques ß1 et ß2; l'acétylcholinestérase; la Na+/K+-ATPase; et le cotransporteur Na-K-2Cl. L'hypertension oculaire est traitée par administration d'ARN interférents selon l'invention.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Rnai-mediated inhibition of ocular targets does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rnai-mediated inhibition of ocular targets, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rnai-mediated inhibition of ocular targets will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1965836

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.